Fate Therapeutics, Inc.FATENASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank29
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-106.08M
Near historical average
Percentile
P29
Within normal range
Streak
3 yr
Consecutive growthContracting
Average
$-100.01M
Historical baseline
PeriodValueYoY Change
2025$-106.08M+13.7%
2024$-122.87M+7.1%
2023$-132.26M+46.7%
2022$-248.21M-52.4%
2021$-162.87M-315.2%
2020$-39.23M+52.8%
2019$-83.17M-115.2%
2018$-38.65M-4.7%
2017$-36.91M-23.7%
2016$-29.82M-